Person: GÜNAYDIN, FATMA ESRA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
GÜNAYDIN
First Name
FATMA ESRA
Name
6 results
Search Results
Now showing 1 - 6 of 6
Publication Fatigue: A forgotten symptom of asthma(Wiley, 2021-03-29) Günaydın, Fatma Esra; Ediger, Dane; Erbay, Müge; GÜNAYDIN, FATMA ESRA; EDİGER, DANE; ERBAY, MÜGE; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı/İmmünolji ve Alerji Hastalıkları Bölümü; 0000-0002-9268-1071; 0000-0002-2954-4293; 0000-0003-3948-7007; HKV-2265-2023; HJA-1363-2022; AAE-9142-2019Objective Fatigue is a common symptom frequently reported in many disorders but little is known about the prevalence of fatigue in asthma. The objective of this study was to determine the prevalence of fatigue in asthmatic patients, the effect of fatigue on asthma quality of life and the relationship between fatigue and anxiety/depressionMaterials and methods This prospective cross-sectional study was conducted in Uludag University Faculty of Medicine, Department of Immunology and Allergic Diseases outpatient clinic from June 2019 to December 2019. Fatigue was assessed using the Checklist Individual Strength-Fatigue (CIS-Fatigue), psychological distress was assessed using the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI) and quality of life were assessed using the Asthma Quality of Life Questionnaire (AQLQ).Results In the present study, a total of 168 patients are included with an average age of 43.8 +/- 4.3 years. Nearly 64.8% of patients had controlled asthma and (35.2%) patients had uncontrolled asthma. Fatigue (CIS-Fatigue >= 27 points) was detected in 62.6% of patients and associated with asthma-related quality of life, asthma control, dyspnea, depression and anxiety (P < 0.05). However, the degree of lung function impairment and asthma severity were not associated with fatigue.Conclusions Fatigue as a symptom is common in asthmatic patients and correlates with asthma-related quality of life, asthma control, dyspnea, depression and anxiety. Future studies are needed to better understand the physical, psychological, behavioural and systemic factors that precipitate or perpetuate fatigue in asthma.Publication Fatigue: A forgotten symptom of asthma(Wiley, 2021-11-01) Gunaydin, Fatma Esra; Ediger, Dane; Erbay, Müge; GÜNAYDIN, FATMA ESRA; EDİGER, DANE; ERBAY, MÜGE; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı/İmmünoloji ve Alerji Bilim Dalı.; 0000-0002-9268-1071; 0000-0002-2954-4293; HKV-2265-2023; AAE-9142-2019; IKM-5924-2023Publication The relationship between serum levels of surfactant protein d in copd exacerbation severity and mortality(Tubitak Scientific & Technological Research Council Turkey, 2019-01-01) Kalkan, Nurdan; Günlüoğlu, Gülşah; Aktepe, Esma Nur; Demirkol, Barış; Altın, Sedat; Günaydın, Fatma Esra; GÜNAYDIN, FATMA ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi; 0000-0002-9268-1071; HKV-2265-2023Background/aim: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. In COPD patients, various inflammatory markers such as cytokines and acute phase proteins, which show systemic inflammation in the circulation, increase during exacerbations. In our study, we aimed to determine the relationship between serum SP-D levels and exacerbation severity, clinical course of the disease, and early mortality after discharge.Materials and methods: Fifty hospitalized patients with COPD acute exacerbation (46 male and 4 female) were recruited in this study. Thirty-three of the subjects (31 male and 2 female) were reevaluated after discharge. Venous blood samples were taken from all patients and followed up for exacerbation frequency, hospital admission, and mortality for 12 months.Results: Serum SP-D levels in the stable period of the patients were lower than exacerbation (P < 0.001). The median exacerbation period SP-D level of the patients admitted to emergency department in the first month was statistically significantly higher than that of the patients who were not admitted (P < 0.05) after discharge. There was a correlation between the rate of emergency admission and serum SP-D levels during the 12-month period after discharge (P = 0.04 (r = 0.29)).Conclusion: Our study showed that serum SP-D was found to be a useful biomarker in predicting emergency admission and predictor of the health status of COPD patients but did not predict early mortality after the exacerbation.Publication Covid-19 treatment at a glance(Aves, 2020-11-01) Arikan, Huseyin; Karadogan, Dilek; Akyil, Fatma Tokgoz; Yüksel, Aycan; Toreyin, Zehra Nur; Gürkan, Canan Gunduz; Marim, Feride; Eyuboglu, Tugba Şişmanlar; Emiralioglu, Nagehan; Gursoy, Tugba Ramasli; Serifoglu, Irem; Sandal, Abdulsamet; Oncel, Asli; Er, Berrin; Köse, Neslihan; Esendagli, Dorina; Hizal, Mina; Er, Aslihan Banu; ; Kaya, İlknur; Ozakinci, Hilal; Sertçelik, Umran Özden; Tuğlu, Hatice Çelik; ; Ataoğlu, Ozlem; Cakir, Ahu Cerit; Toptay, Huseyin; Ercelik, Merve; Develi, Elif; Çelik, Selman; Karakaş, Fatma Gülsüm; Yildirim, Halime; Güven, Damla Karadeniz; Çetin, Nazlı; Kucukyurt, Sumeyye Nur Aslan; Elverişli, Mehmet Fatih; Gülhan, Pinar Yildiz; Akgün, Metin; Özürk, Nilufer Aylin Acet; Günaydin, Fatma Esra; GÜNAYDIN, FATMA ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi; 0000-0001-8837-2527; 0000-0001-5321-3964; 0000-0002-3793-9834; 0000-0003-0183-6232; 0000-0002-4746-529X; 0000-0001-7284-4999; 0000-0002-1405-8401; 0000-0002-7064-7585; 0000-0002-2256-3619; 0000-0002-6619-2952; 0000-0002-6922-4948; 0000-0002-7832-6233; 0000-0002-9268-1071; 0000-0002-0227-9215; 0000-0001-8394-6544; 0000-0003-1887-7989; 0000-0002-9008-7909; 0000-0002-9077-0580; 0000-0002-5347-2365; 0000-0003-3404-4274; HHS-7147-2022; AAO-8667-2020; AAC-2765-2021; AAA-7773-2020; HKV-2265-2023; ABA-4700-2020; G-2709-2018; AAK-5467-2020; AAH-4957-2020; ADF-0894-2022; ABB-3303-2021; HHC-7785-2022; ABG-9411-2021; KHW-6493-2024; AAS-6628-2021; S-7221-2016; HLX-2603-2023; AAW-3004-2020; I-9505-2013; HGA-6716-2022; X-1418-2018; ABF-9398-2020; A-9993-2008; AAB-8485-2022; ACB-2570-2022As coronavirus disease 2019 (COVID-19) spreads across the world, the ongoing clinical trials are leading to a big race worldwide to develop a treatment that will help control the pandemic. Unfortunately, COVID-19 does not have any known effective treatment with reliable study results yet. In this pandemic, there is not a lot of time to develop a new specific agent because of the rapid spread of the disease. The process of developing a vaccine is long and requires hard work. Although the pathophysiology of the disease is not fully understood, some of the proposed treatment alternatives are based on old evidence and some have been used with the idea that they might work owing to their mechanism of action. The efficacy, reliability, and safety of the currently available treatment alternatives are therefore a matter of debate. Currently, the main therapies used in the treatment of COVID-19 are antiviral drugs and chloroquine/hydroxychloroquine. Other proposed options include tocilizumab, convalescent plasma, and steroids, but the mainstay of the treatment in intensive care units remains supportive therapies.Publication Hypersensitivity reactions to local anesthetics: A 5-year observational study in a Turkish tertiary referral center(Turkish Natl Soc Allergy And Clinical Immunology, 2023-12-08) Erbay, Müge; Şeker, Ümmühan; Gunaydın, Fatma Esra; GÜNAYDIN, FATMA ESRA; Ediger, Dane; EDİGER, DANE; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmunoloji Anabilim Dalı.Objective: Local anesthetics are broadly used in various health care settings with high probability of lifetime exposure. The main aim of this study was to determine the characteristics and risk factors of the patients presenting to our allergy outpatient clinic due to suspected hypersensitivity to local anesthetics. Materials and Methods: We retrospectively evaluated the clinical data and test results obtained from patients who had presented to our allergy outpatient clinic for allergological work-up of local anesthetics from 2015 to 2020. Results: A total of 289 subjects were included. The most common referral reason was a history of non-local anesthetic drug hypersensitivity reaction (65.7%, n=190). Twenty-five out of 289 (8.65%) patients had positivity for at least one of the tested drugs in skin prick test/ intradermal test/ subcutaneous drug provocation test. Of these 25 patients, 4 (16%) had a history of DHR to LA and 9 (36%) had a history of multiple drug hypersensitivity (MDH). Allergy to local anesthetics was observed in only 13 (18.6%) of 70 patients with a history of local anesthetic hypersensitivity reaction. Patients with atopy were 5.3 times more likely to have local anesthetic hypersensitivity (odds ratio: 5.254; 95% CI: 1.316-20.974; p=0.019). Cross-reactivity among amide-local anesthetics without a distinct predictive pattern has also been demonstrated in 3 patients. Conclusion: Most patients who report local anesthetic allergy can tolerate local anesthetics without having a hypersensitivity reaction. Atopic status is associated with increased risk of a hypersensitivity reaction to local anesthetics. Atopic patients are candidates for performing allergy tests to local anesthetics to enable appropriate counseling.Publication Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab(Turkish Assoc Tuberculosis & Thorax, 2023-01-01) Pekbak, Gülseren; PEKBAK, GÜLSEREN; Ediger, Dane; ERBAY, MÜGE; Günaydın, Fatma Esra; GÜNAYDIN, FATMA ESRA; Erbay, Müge; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Alerji ve İmmunoloji Anabilim Dalı.; 0000-0002-2954-4293; 0000-0002-9268-1071; HJA-1363-2022Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumabIntroduction: Omalizumab, a humanized monoclonal anti-IgE antibody, has largely demonstrated its efficacy in severe allergic asthma. There are limited data about the effectiveness of omalizumab in patients with non-atopic severe persistent asthma. In this study, we aimed to determine the effect of omalizumab in patients with non-atopic severe asthma and compare the data obtained with those in patients with allergic severe asthma.Materials and Methods: This study was an observational, retrospective, tertiary single-center study that assessed and compared the clinical outcome of adult patients with severe asthma (165 atopic and 41 non-atopic) who have been on omalizumab for one year or longer between January 2008 and January 2020. Effectiveness was assessed by considering symptom scores (GINA symptom control score), daily systemic corticosteroids (SCS) dosage, blood eosinophil counts, pulmonary function, and number of severe exacerbations and hospitalizations within the last one year.Results: Omalizumab exhibited significant improvement in the clinical status of non-atopic asthma patients as measured by GINA symptom score [decreased from 3.77 +/- 0.63 to 1.36 +/- 1.27 (p< 0.001)], the number of emergency room visits for asthma [decreased from 11.25 +/- 14.69 to 0.25 +/- 0.55 (p< 0.001)], and the number of hospitalizations [decreased from 1.17 +/- 2.87 to 0.14 +/- 0.36 (p= 0.036)]. These results were not significantly different from those obtained in allergic asthma patients. FEV1 improved significantly from 2.08 +/- 0.86 to 2.14 +/- 0.84 (p= 0.041) and oral corticosteroid doses decreased significantly from 1.67 +/- 7.49 to 0.46 +/- 2.74 (p= 0.015) in the only atopic group.Conclusion: Omalizumab, which is a proven and effective treatment option for allergic asthma, may also be an efficacious alternative option in non-atopic severe asthma.